Skip to content

Advertisement

  • Technical Note
  • Open Access

Determination of quantitative and site-specific DNA methylation of perforinby pyrosequencing

  • 1,
  • 1,
  • 1 and
  • 1Email author
BMC Research Notes20092:104

https://doi.org/10.1186/1756-0500-2-104

©  Rajeevan et al; licensee BioMed Central Ltd. 2009

  • Received: 12 May 2009
  • Accepted: 12 June 2009
  • Published:

Abstract

Background

Differential expression of perforin (PRF1), a gene with a pivotal role in immune surveillance, can be attributed to differential methylation of CpG sites in its promoter region. A reproducible method for quantitative and CpG site-specific determination of perforin methylation is required for molecular epidemiologic studies of chronic diseases with immune dysfunction.

Findings

We developed a pyrosequencing based method to quantify site-specific methylation levels in 32 out of 34 CpG sites in the PRF1 promoter, and also compared methylation pattern in DNAs extracted from whole blood drawn into PAXgene blood DNA tubes (whole blood DNA) or DNA extracted from peripheral blood mononuclear cells (PBMC DNA) from the same normal subjects. Sodium bisulfite treatment of DNA and touchdown PCR were highly reproducible (coefficient of variation 1.63 to 2.18%) to preserve methylation information. Application of optimized pyrosequencing protocol to whole blood DNA revealed that methylation level varied along the promoter in normal subjects with extremely high methylation (mean 86%; range 82–92%) in the distal enhancer region (CpG sites 1–10), a variable methylation (range 49%–83%) in the methylation sensitive region (CpG sites 11–17), and a progressively declining methylation level (range 12%–80%) in the proximal promoter region (CpG sites 18–32) of PRF1. This pattern of methylation remained the same between whole blood and PBMC DNAs, but the absolute values of methylation in 30 out of 32 CpG sites differed significantly, with higher values for all CpG sites in the whole blood DNA.

Conclusion

This reproducible, site-specific and quantitative method for methylation determination of PRF1 based on pyrosequencing without cloning is well suited for large-scale molecular epidemiologic studies of diseases with immune dysfunction. PBMC DNA may be better suited than whole blood DNA for examining methylation levels in genes associated with immune function.

Keywords

  • Methylation Level
  • Chronic Fatigue Syndrome
  • Bisulfite
  • Proximal Promoter Region
  • Bisulfite Treatment

Background

Perforin (PRF1), a major immune surveillance gene, is a candidate gene for the identification of methylation markers, and for investigating the pathophysiology of a number of chronic diseases with suspected immune dysfunction [1–9]. Earlier studies to assess PRF1 promoter methylation used bisulfite sequencing of cloned PCR products [5]. Cloning PCR products for quantitative site-specific determination of CpG methylation is laborious, and can be inaccurate due to under-representation of the number of clones analyzed. On the other hand, pyrosequencing technology offers a convenient way for quantitative site-specific determination of CpG methylation but this technology has not yet been developed for the study of PRF1. Pyrosequencing determines the ratio of C/T base changes after bisulfite treatment, reflecting the proportion of unmethylated and methylated cytosines at each CpG site in the original sequence [10].

Several factors like sample collection, bisulfite treatment, and PCR can affect the reproducibility of methylation levels determined by pyrosequencing. Blood is a non-invasive source of sample for molecular epidemiologic studies. Usually, blood is drawn into blood collection tubes followed by separation of peripheral blood mononuclear cells (PBMCs) to extract DNA for molecular genetic studies including methylation. Recently, to minimize variability in primary blood samples from multicenter studies and to enable transport and storage, blood is drawn into specialized tubes like PAXgene blood DNA tubes containing additives for cell lysis. These PAXgene blood DNA tubes are then transported to laboratories where DNA is extracted directly from the whole blood without PBMC separation. DNA extracted from PAXgene blood DNA tubes thus represents the contribution of all blood cell types and have been successfully used for genotyping. However, the impact of these blood collection procedures for DNA (whole blood vs PBMC DNA) on methylation levels has not been reported.

In this study, we developed a pyrosequencing based methylation assay for a total of 32 out of 34 CpG sites in the promoter region of PRF1. The assay is highly reproducible with respect to bisulfite treatment, and PCR. Examination of methylation levels in normal subjects showed that methylation levels differ significantly between DNAs extracted from PBMCs and whole blood for all 32 CpG sites except two, although the methylation pattern remained similar over the 1.4 kb promoter region. These results show that site-specific assessment of CpG methylation in PRF1 can be reproducibly assessed by pyrosequencing without cloning, and that PBMC DNA may be better suited than whole blood DNA for molecular epidemiologic studies on methylation levels of genes associated with immune dysfunction.

Methods

Pyrosequencing strategy

Bisulfite converted sequences were simulated by a previously reported Microsoft Word bisulfite macro [11] followed by pyrosequencing assay design using Assay Design Software (Biotage, Uppsala, Sweden). Both top and bottom strands were used for designing primers to cover all the 34 CpG sites in 1.4 kb PRF1 promoter. Similarly, both forward and reverse sequencing designs were employed with 5'biotinylation of the reverse or forward PCR primer respectively. All primers were synthesized at the Biotechnology Core Facility, Centers for Disease Control & Prevention, Atlanta, GA.

DNA samples and bisulfite treatment

Blood drawn in PAXgene blood DNA tubes (Qiagen, CA) for DNA extraction were obtained from 20 subjects who took part in the Chronic Fatigue Syndrome Study at the Centers for Disease Control and Prevention, Atlanta, GA. From five of these subjects classified as normal, blood was also drawn in BD Vacutainer CPT tubes (BD, NJ) followed by separation of PBMC for DNA extraction. DNA from PAXgene blood tubes was extracted using PAXgene blood DNA kit (Qiagen) whereas DNA from PBMCs was extracted using Roche DNA isolation kit for mammalian blood (Roche Applied Science, IN). DNA was quantified using NanoDrop ND-100 Spectrophotometer (Thermo Fisher Scientific, MA) prior to bisulfite treatment. DNA (200 ng/reaction) was bisulfite treated using the EZ DNA Methylation Kit (Zymo Research, CA), according to the manufacturer's instructions. Bisulfite treated DNA (BST-DNA) was eluted twice in 10 μl of the manufacturer's M-Elution Buffer (20 μl final volume), and was stored in aliquots at -20°C until use.

PCR and pyrosequencing

Each 100 μl PCR contained 1.5 mM MgCl2, 0.2 mM dNTP, 0.05 U/μl Platinum Taq DNA polymerase (Invitrogen, CA) and 0.2 μM each of forward and reverse primers (Table 1) and 5 μl of BST-DNA. In this study, we used a touchdown PCR cycling approach previously reported for BST-DNA [12] for all amplicons except amplicon F (Table 1). Touchdown PCR consisted of one cycle of 94°C for 5 min for the initial denaturation step. This was followed by 5 cycles each of denaturation at 94°C for 30 s, varying annealing for 30 s, and extension at 72°C for 30 s. Annealing temperatures for the touchdown portion were provided as follows: 65°C for 5 cycles, 62°C for 5 cycles, 59°C for 5 cycles, 56°C for 5 cycles and 52°C for 5 cycles. A further 50 cycles constituted the following: 94°C for 30 s, 50°C for 30 s and 72°C for 30 s. PCR was terminated after a final cycle at 72°C for 7 min. PCR cycling conditions for amplicon F consisted of the following: one cycle of 95°C for 2 min; 50 cycles of 95°C for 15 s, 52°C for 30 s, 72°C for 30 s; one cycle of 72°C for 5 min.
Table 1

Primer sets for determination of perforin CpG methylation by pyrosequencing

Amplicon*

(bp)

PCR primers† (5' to 3')

Sequencing primers‡

CpG site # and nucleotide

position∞

A (236)

FW: TTG ATT TTA TAG GTG AGG AAA TTA

RV: TTC CAA CTA TCA CCC ATA ACC TAA

TTT TAT AGG TGA GGA AAT TA

A Y GTTTAGAAAGGGGGTTGATATTTAT Y GT Y GTGAGGTATA Y GG

ATT TTT ATG TTT TTT AAA T

Y GGTTTTTTTGTTA

1, -1365; 2, -1339; 3, -1336; 4, -1325

6, -1231

B (226)

FW: ATG TTG AGG TTG TGA GGA GTT TT

RV: AAA TTC CAA AAT CCT CTC TTT AAT

GAA GTT TTG TAA AGT ATT TG

Y GGGAAAAGAG

5, -1267

C (196)

FW: TTG GAA AGT GAT TAG GAG GTT GTA

RV: CAA ACT CCA AAC CAC ATA TAA CAT

AGA GGG TGG GGA TATT

G Y GGAGAGAAGATGGGGTTAGATTT Y G

GTT TTT GTT TTT GTA AGA GT

AGGGA Y GGAAGTAGGGATATAAA Y G

7, -1110; 8, -1088

9, -1045; 10, -1027

D (91)

FW: GAG GTT TTT ATG GGT GGA GTG AT

RV:CAC CTC CTC CCT TAC CCA ACT A

TTG GGG GGT AAA ATT

ATA Y GGTTTT T

11, -876

E (256)

FW: TTT TGA GTG GGA GAA GAG AGA TGT

RV:CCC CAC CCT AAC CTC AAA CA

GTG AGA GTG GTT TGG TAG

TAT Y GGAGG

TTG GTT TTA GTT TTG TTG A

GGT Y GTGGGT

AGG ATA GTT AGT GGT TTT TA

Y GTTGGTTTTAGTTTTGTTG

12, -776

13, -774

14, -720

F (167)

FW: TGG AGG TTA TTG GTT GTT TTT ATA

RV: TAA CCA TTC CCT CCT CCC TAA ATA

GGT TAT TGG TTG TTT TTA TA

AAG Y GAGGAG T AGGAGTTTTTGTT Y GAGGAATATGTTTGGAGTT Y GG

15, -691; 16, -670; 17, -650

G (300)

FW: TTA GGG AGG AGG GAA TGG TTA TAG

RV: AAC CAA CAA AAC CAT CTC CTT ACT

TAG TTT ATA TTG TTG GTG TA

TAAT Y GAGTTGTTTAAGTTT Y GG Y GGTTTGG Y G

18, -397; 19, -381; 20, -378; 21, -370

H (300)

FW: TTT AGG GAG GAG GGA ATG GTT ATA

RV: ACC AAC AAA ACC ATC TCC TTA CTT

TAC TTC TAA TAC ACA ACA TC

R CATATATAAAATATAAAAAACAAACAAAAAC R AC R AC

24, -313; 23, -345; 22, -348

I (233)

FW: GGG GAT TTA GGG TAT ATA GG

RV: AAA CCC TAC CAA TCC ACA CTA CT

GGG GAT TTA GGG TAT AT

AGG Y GGAGGAGGG Y GGGG Y GTTGAGGATTTTGAGATT Y GGT

28, -219; 27, -229; 26, -234; 25, -253

J (237)

FW: TGG TTT TGT TGG TTT GTT TAT TAA

RV: CCC CAA CTA TAA TCA CAA ATC CTT

CAA AAC CAA AAA CTC ATC T

ACC R AATAAAACTACTAAAACTC R

CCT CAA CCC TCA TCC

R ACTCCCCACTAACAACCCTCAAAAAAC R AAC

30, -180; 29, -200

32, -122; 31, -150

K (97)

FW: TTG AGG ATA GGG TGG GTG TT

RV: CCA CCA CTC ACA TCA CTT CTA CTT

GGA TAG GGT GGG TGT T

Y GTGGGAGGGGAGAGTATAAAGGATTTGTGATTATAGTTGGGGG Y

33, -92; 34, -48

*Nucleotide positions of amplicons from 5' → 3' direction of the top or bottom strand used for assay design. A, 20 – 255; B, 1186 – 1411; C, 250 – 445; D, 826 – 916; E, 569 – 824; F, 692 – 858; G, 838 – 1137; H, 837 – 1136; I, 200 – 432; J, 1124 – 1360; K, 1298 – 1394. Amplicons in bold (B, D, E and I) represent those amplicons designed using the bottom strand after bisulfite conversion.

†Fw, forward primer; Rv, reverse primer. Biotinylated primers are indicated in bold.

†Sequencing primers are indicated in bold. Sequences to analyze are italicized with the CpG sites (Y or R) underlined.

∞Indicates CpG site number and corresponding nucleotide location from the distal end of the promoter. Numbering is based on the top strand used for assay design.

Pyrosequencing was performed according to the manufacturer's instructions. The PyroGold kit was used in conjunction with the PSQ 96MA instrument (Biotage), and each pyrosequencing reaction used 20 μl of PCR product. Biotinylated single strand DNA was separated by immobilizing the PCR product on streptavidin coated Sepharose High Performance beads (Amersham Biosciences, NJ) and strand separated by denaturation with 0.2 N NaOH. After denaturation, the biotinylated strand was annealed to sequencing primer (0.5 μM final concentration), and subjected to sequencing using an automatically generated nucleotide dispensation order for the "sequence to analyze" corresponding to each reaction (Table 1). Pyrograms were analyzed in "Allele Quantification" mode in order to determine the percentage of C/T, corresponding to the percentages of methylated and unmethylated C at each of the CpG sites. As a positive control for PCR and pyrosequencing, we used previously reported PCR and sequencing primers to detect two CpG sites in CDNK2A [13].

Assay reproducibility

1. Bisulfite reproducibility

The impact of bisulfite treatment on assay reproducibility was tested using the PCR and pyrosequencing conditions for CpG sites 18–21 in amplicon G with whole blood DNA from 20 subjects. The same DNA was bisulfite treated on three separate days. Each day, 20 individual bisulfite reactions were set up with 200 ng DNA/reaction. BST-DNA from each of the three days was simultaneously subjected to PCR in the same thermocycler to eliminate PCR-to-PCR variability. All PCR products were used for pyrosequencing in duplicate, giving a mean of 6 pyrogram readings per CpG site for all three sets of BST-DNA per subject. Day-to-day variation in bisulfite reaction was expressed as coefficient of variation (CV) calculated as the percentage of standard deviation to its mean

2. Touchdown PCR reproducibility

The impact of PCR-to-PCR variability, expressed in terms of CV, was also tested for CpG sites 18–21 in amplicon G on three different days using the same BST-DNA. Touchdown PCR reproducibility was done with whole blood DNA from 10 subjects. Each PCR product was subjected to pyrosequencing in duplicate, yielding a mean of 6 values per CpG site for PCR from all three days per subject.

Evaluation of methylation pattern in the PRF1 by pyrosequencing

A small pilot study consisting of five normal subjects was conducted to evaluate the robustness of the optimized conditions to determine the methylation level/pattern in the PRF1 promoter for 32 CpG sites. This pilot study also examined the impact of DNA from whole blood or PBMC on PRF1 methylation profile in normal subjects. For each subject, two separate bisulfite reactions were set up, followed by corresponding PCR and pyrosequencing reactions yielding a mean of 2 values per CpG site. Both whole blood and PBMC DNAs were treated similarly to generate the PRF1 methylation profiles.

Results

The PRF1 promoter spans about 1.4 kb (-1411 to +1) upstream of the transcriptional start site and harbors a number of transcription factor binding sites [14, 15]. Out of a total of 34 CpG sites in the PRF1 promoter, 10 are in the distal promoter region containing enhancer elements (CpG sites 1–10), 17 are in the proximal promoter region harboring repetitive elements (CpG sites 18–34), and seven (CpG sites 11–17) are in the methylation sensitive region (MSR) located between the distal and proximal promoter regions (Figure 1). Eleven amplicons A to K and 16 sequencing primers were designed to cover all 34 CpG sites (Figure 1; Table 1).
Figure 1
Figure 1

The perforin (PRF1) promoter (1411 bp) with locations of 34 CpG and several putative transcription factor binding sites. Ten CpGs are located in the enhancer element region, seven in the methylation-sensitive region (MSR) and 17 in the repetitive element region. "+1" indicates the transcription start site. Lower case letters from 'a -to- l' represent different transcription factor binding sites [14, 15]: a, inducer response motif; b, γ-IFN responsive element; c, CRE element; d, AP-2 element; e, TPA-responsive element; f, STAT5-responsive enhancer; g, CCAT box; h, C-fos enhancer; i, 19 homologous repeats; j, three repeats; k, two repeats; l, GC box. Upper case letters from 'A -to- K' represent amplicons (not scaled to size) designed to detect different CpG sites.

We compared the performance of PCR with single annealing temperature and touchdown PCR and found that PCR cycling program with a single annealing temperature often generated multiple bands, particularly with amplicon E, which is rich in AT content (70%). On the other hand, touchdown PCR consistently generated specific products of expected size with all amplicons except amplicon F, for which PCR with single annealing temperature consistently resulted in specific product than touchdown PCR. Thus, we used touchdown PCR to generate all amplicons, except amplicon F which was generated with PCR following single annealing temperature. Pyrosequencing reactions for all CpG sites were successful except CpG sites 33 and 34 in amplicon K, although amplicon K was successfully generated by the touchdown PCR.

Variability due to bisulfite treatment was tested for four CpG sites (sites 18–21) in amplicon G using whole blood DNA from 20 individual subjects. Variability due to bisulfite treatment was found to be minimal for all four CpG sites in amplicon G, (mean CV of 2.18%, and CVs for individual CpG sites ranged from 1.97% to 2.37%, Figure 2). Variability due to touchdown PCR was also assessed for CPG sites 18–21 using whole blood DNA from 10 subjects and was found to be very low for all four CpG sites in amplicon G, with a mean CV of 1.63%, and with CVs for individual CpG sites ranging from 1.34% to 1.86% (Figure 3).
Figure 2
Figure 2

Reproducibility of bisulfite treatment determined using amplicon G. Mean methylation level (%) ± SD for four CpG sites 18–21 are shown.

Figure 3
Figure 3

Reproducibility of touchdown PCR determined using amplicon G. Mean methylation level (%) ± SD for four CpG sites 18 to 21 are shown.

Application of the optimized conditions to generate PRF1 methylation profile for 32 CpG sites using whole blood DNA from five normal subjects revealed that the methylation levels varied along the promoter with extremely high methylation (mean 86%; range 82%–92%) in the distal enhancer region covering CpG sites 1–10 (Figure 4). Methylation levels in the MSR covering CpG sites 11–17 appeared to vary up and down from a low of 49% (CV = 1.49%) at CpG site 11 to a high of 83% (CV = 0.84%) at CpG site 16 (mean methylation level for sites 11–17 = 67%). Interestingly, methylation levels in the proximal promoter region covering CpG sites 18–32 progressively declined from a high of 73–80% at sites 18–19 to as low as 12–20% at sites 30 and 32 (mean methylation at sites 18–32 = 54%). Among specific sites, CpG sites 11, 15, 25, 29 and 30 showed sharp decline in methylation levels compared to adjacent CpG sites. Perforin methylation profile over the same 32 CpG sites in the same five subjects using PBMC DNA appeared very similar i.e., extremely high methylation in the distal enhancer region, a variable methylation in the MSR, and progressively declining methylation in the proximal promoter region. However, except for CpG sites 5 and 15, the absolute methylation levels at each CpG site as determined from the whole blood and PBMC DNAs differed significantly, with higher values for all CpG sites in the whole blood DNA (Figure 4).
Figure 4
Figure 4

The pattern of methylation in 32 CpG sites in 1.4 kb PRF1 promoter using DNA from whole blood and PBMCs from normal subjects. Y-axis, methylation level (%) ± SD. X-axis, CpG sites 1–32. Methylation levels at each CpG site represent mean of 5 normal subjects.

Discussion

Analytical procedures for sensitive and site-specific quantitative determination of CpG methylation are influenced by several factors, all of which require careful experimental optimization and validation before the assay can be applied to valuable, and often limited clinical samples in large-scale molecular epidemiologic studies. A number of PCR-based methylation assays utilize bisulfite treatment to preserve the methylation signature of the original DNA. Bisulfite treatment selectively converts unmethylated cytosines to uracil. This base modification results in reduced sequence complexity, which often makes the development of methylation assays difficult due to diminished flexibility in designing quality PCR and sequencing primers, allele-specific PCR biases, and reduced signal strength or abnormally shaped sequencing reactions [16, 17]. We considered these factors while developing a pyrosequencing assay to determine the methylation status of PRF1, an important gene in immune surveillance.

Pyrosequencing assay was designed for all 34 CpG sites in the PRF1 promoter, of which seven CpG sites form a functionally significant subset in the MSR of the promoter. We successfully optimized several steps of the pyrosequencing technology to obtain highly reproducible methylation levels for each of the 32 out of 34 CpG sites. Bisulfite treatment resulted in minimal day-to-day variation (CV 2.18%) that was comparable to the minimal reaction-to-reaction variation in bisulfite treatment as determined by fluorescent probe based quantitative version of methylation-sensitive PCR (MSP, MethyLight assay) [18]. A touchdown PCR approach has been recommended for overcoming PCR biases in reactions using BST-DNA template [12], but the reproducibility of touchdown PCR has not been examined with BST-DNA. We found that touchdown PCR helped to overcome problems with PCR product specificity, and resulted in highly reproducible results from PCR-to-PCR on different days (CV 1.63%).

In this study, the PRF1 methylation pattern identified using both whole blood and PBMC DNAs from normal subjects appeared similar throughout the promoter region in terms of extremely high methylation in distal enhancer region, variable methylation in the MSR, and progressively declining methylation in the proximal promoter region. Except CpG sites 5 and 15, the absolute levels of methylation at each of these CpG sites, however, differed between whole blood and PBMC DNAs, with higher methylation levels obtained using whole blood DNA. We have not investigated the factors that contribute to this similar pattern but different levels in methylation along the PRF1 promoter between whole blood and PBMC DNAs but it is likely to be related to differences in cell types between these samples from the same subject. In a previous study that used bisulfite sequencing followed by cloning, CpG site 14 was found to be the most highly methylated (> 50%) in the MSR of CD4+ T and CD8+ T cells of normal subjects [5]. On the contrary, the most highly methylated CpG site in the MSR in normal subjects in this study was found to be CpG site 16 located 70 bases away from CpG site 14. These differences may be related to differences in the subjects, cell populations or quantitative nature of the assays employed between the studies. The pysosequencing assay described in this report is highly suitable to quantify differences in the methylation of PRF1 in the various sub-populations of cells in blood from normal and subjects with chronic diseases of immune dysfunction. Further, the study suggests that blood drawn in PAXgene blood DNA tubes may be inappropriate for DNA methylation studies of genes with immune function.

We have not compared the estimates of PRF1 methylation determined by pyrosequencing with other method such as MSP or combined bisulfite restriction analysis since our reproducibility data agree with other reports supporting the reliability of pyrosequencing for quantitative and efficient screening of multiple CpG sites in candidate genes studies [13, 19–21]. Further, pyrosequencing has been used as a reference method for validation of other methods and has been shown to have excellent specificity and sensitivity for diagnostic uses [22, 23]. A number of dilution and titration experiments with known amounts of methylated and unmethylated DNA or cells with methylated viral DNA in the background of uninfected cells also support the reliability of pyrosequencing for the sensitive and specific determination of methylation at multiple CpG sites [10, 13, 18, 23, 24].

Conclusion

In conclusion, we have developed a highly reproducible procedure based on pyrosequencing technology for the site-specific and quantitative determination of methylation levels in 32 CpG sites in the PRF1 promoter. In normal subjects, methylation levels along the 1.4 kb promoter varied similarly in DNAs from whole blood and PBMC but differed in absolute methylation levels, suggesting collection of blood in devices like PAXgene blood DNA tube may not be appropriate for methylation studies of immune function related genes. This method can be applied to clinical samples in order to systematically evaluate the significance of multiple CpG sites in perforin which will improve our understanding of the pathophysiology of chronic disorders with alterations in immune function.

Declarations

Acknowledgements

Support for S. Narasimhan and VR. Falkenberg was provided by the research participation program at the National Center for Zoonotic Vector-Borne and Enteric Diseases, Centers for Disease Control and Prevention (CDC), Division of Viral and Rickettsial Diseases, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agency.

Authors’ Affiliations

(1)
Division of Viral and Rickettsial Diseases, National Center for Zoonotic Vector-Borne and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA

References

  1. Gulan G, Ravlic-Gulan J, Strbo N, Sotosek V, Nemec B, Matovinovic D, et al, et al: Systemic and local expression of perforin in lymphocyte subsets in acute and chronic rheumatoid arthritis. J Rheumatol. 2003, 30: 660-670.PubMedGoogle Scholar
  2. Kaplan MJ, Lu Q, Wu A, Attwood J, Richardson B: Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol. 2004, 172: 3652-3661.View ArticlePubMedGoogle Scholar
  3. Kastelan M, Prpic ML, Gruber F, Zamolo G, Zauhar G, Coklo M, et al, et al: Perforin expression is upregulated in the epidermis of psoriatic lesions. Br J Dermatol. 2004, 151: 831-836. 10.1111/j.1365-2133.2004.06168.x.View ArticlePubMedGoogle Scholar
  4. Li M, Yang Q, Zhang Y: Effects of CD134 monoclonal antibody on hemolysis activities and expression of perforin in peripheral blood mononuclear cells of systemic lupus erythematosus patients. Hybridoma (Larchmt). 2007, 26: 191-200. 10.1089/hyb.2007.010.View ArticleGoogle Scholar
  5. Lu Q, Wu A, Ray D, Deng C, Attwood J, Hanash S, et al, et al: DNA methylation and chromatin structure regulate T cell perforin gene expression. J Immunol. 2003, 170: 5124-5132.View ArticlePubMedGoogle Scholar
  6. Maher KJ, Klimas NG, Fletcher MA: Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol. 2005, 142: 505-511.PubMed CentralPubMedGoogle Scholar
  7. Skarpa I, Rubesa G, Moro L, Manestar D, Petrovecki M, Rukavina D: Changes of cytolytic cells and perforin expression in patients with posttraumatic stress disorder. Croat Med J. 2001, 42: 551-555.PubMedGoogle Scholar
  8. Steinau M, Unger ER, Vernon SD, Jones JF, Rajeevan MS: Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome. J Mol Med. 2004, 82: 750-755. 10.1007/s00109-004-0586-4.View ArticlePubMedGoogle Scholar
  9. Trapani JA, Voskoboinik I: The complex issue of regulating perforin expression. Trends Immunol. 2007, 28: 243-245. 10.1016/j.it.2007.04.003.View ArticlePubMedGoogle Scholar
  10. Rajeevan MS, Swan DC, Duncan K, Lee DR, Limor JR, Unger ER: Quantitation of site-specific HPV 16 DNA methylation by pyrosequencing. J Virol Methods. 2006, 138: 170-176. 10.1016/j.jviromet.2006.08.012.View ArticlePubMedGoogle Scholar
  11. Singal R, Grimes SR: Microsoft Word macro for analysis of cytosine methylation by the bisulfite deamination reaction. Biotechniques. 2001, 30: 116-120.PubMedGoogle Scholar
  12. Shen L, Guo Y, Chen X, Ahmed S, Issa JP: Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques. 2007, 42: 48-10.2144/000112312. 50, 52.View ArticlePubMedGoogle Scholar
  13. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R: Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques. 2003, 35: 146-150.PubMedGoogle Scholar
  14. Lichtenheld MG, Podack ER: Structure of the human perforin gene. A simple gene organization with interesting potential regulatory sequences. J Immunol. 1989, 143: 4267-4274.PubMedGoogle Scholar
  15. Zhang J, Scordi I, Smyth MJ, Lichtenheld MG: Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med. 1999, 190: 1297-1308. 10.1084/jem.190.9.1297.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Gharizadeh B, Akhras M, Nourizad N, Ghaderi M, Yasuda K, Nyren P, et al, et al: Methodological improvements of pyrosequencing technology. J Biotechnol. 2006, 124: 504-511. 10.1016/j.jbiotec.2006.01.025.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Mashayekhi F, Ronaghi M: Analysis of read length limiting factors in Pyrosequencing chemistry. Anal Biochem. 2007, 363: 275-287. 10.1016/j.ab.2007.02.002.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, et al, et al: Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006, 8: 209-217. 10.2353/jmoldx.2006.050135.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Dupont JM, Tost J, Jammes H, Gut IG: De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal Biochem. 2004, 333: 119-127. 10.1016/j.ab.2004.05.007.View ArticlePubMedGoogle Scholar
  20. Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J, et al, et al: Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007, 9: 368-381. 10.2353/jmoldx.2007.060167.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Tost J, Gut IG: DNA methylation analysis by pyrosequencing. Nat Protoc. 2007, 2: 2265-2275. 10.1038/nprot.2007.314.View ArticlePubMedGoogle Scholar
  22. Irizarry RA, Ladd-Acosta C, Carvalho B, Wu H, Brandenburg SA, Jeddeloh JA, et al, et al: Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res. 2008, 18: 780-790. 10.1101/gr.7301508.PubMed CentralView ArticlePubMedGoogle Scholar
  23. White HE, Durston VJ, Harvey JF, Cross NC: Quantitative analysis of SNRPN(correction of SRNPN) gene methylation by pyrosequencing as a diagnostic test for Prader-Willi syndrome and Angelman syndrome. Clin Chem. 2006, 52: 1005-1013. 10.1373/clinchem.2005.065086.View ArticlePubMedGoogle Scholar
  24. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P: Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis. 2002, 23: 4072-4079. 10.1002/elps.200290023.View ArticlePubMedGoogle Scholar

Copyright

© Rajeevan et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Research Notes

ISSN: 1756-0500

Contact us